Kymera Therapeutics Inc Environmental Analytics
Environmental and financial analysis dashboard for Kymera Therapeutics Inc. Industry: PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES
Company Overview for Kymera Therapeutics Inc
Highlights
Showing data for FY2022
Operational Environmental Cost
$0.52m
Operational Environmental Cost Intensity
1.11%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$0.38m
Decoupling Rate (2020-2022)
-63%
Adjusted EBITDA
$-152m
Adjusted EBITDA Margin
-325%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| 156.13% | -35.55% | 47.80% | ||
| 0.15% | 0.17% | 0.17% | 0.15% | |
| 352.48% | 5.20% | 53.50% | ||
| 0.27% | 0.57% | 0.93% | 0.85% | |
| $0m | $1m | $1m | $1m | |
| 283.70% | -4.33% | 52.61% | ||
| 0.42% | 0.75% | 1.11% | 1.01% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
-325%
Adjusted EBIT Margin
-331%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$34m | $73m | $47m | $79m | |
| 114.02% | -35.70% | 67.82% | ||
$78m | $170m | $198m | $222m | |
| 228.45% | 234.07% | 423.87% | 282.21% | |
$-44m | $-98m | $-152m | $-143m | |
| -128.45% | -134.07% | -323.87% | -182.21% | |
$-45m | $-100m | $-155m | $-147m | |
| -133.63% | -137.36% | -330.23% | -186.74% | |
| ENVIRONMENTAL COST DATA | ||||
$0m | $1m | $1m | $1m | |
| 0.42% | 0.75% | 1.11% | 1.01% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$-44m | $-98m | $-152m | $-144m | |
| -128.86% | -134.81% | -324.98% | -183.22% | |
$-46m | $-101m | $-155m | $-148m | |
| -134.04% | -138.10% | -331.34% | -187.75% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
RESEARCH AND EXPERIMENTAL DEVELOPMENT ON NATURAL SCIENCES AND ENGINEERING
Scope 1 (% of Sales)
0.17%
Scope 2 (% of Sales)
0.93%
Operational Environmental Cost Intensity
1.11%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
Kymera Therapeutics Inc | US | $1m | 1.11% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022